spacer
home > epc > autumn 2008 > home work
PUBLICATIONS
European Pharmaceutical Contractor

Home Work

In recent decades the types of therapy in research and the marketplace have undergone some radical transformations. Where most therapies were once squarely aimed at endemic diseases of the West, the recent biotechnology revolution has hugely increased the number of therapeutic targets, with more complex medicines – often parenteral – aimed at less common illnesses or at more specific sub groups of patients with more common conditions. For example, we are seeing oncology therapies targeting smaller sub groups of patients, the rise of therapies for orphan indications, the targeting of antibodies and proteins for specific complications of illness such as preventing SLE crisis and so on. The drive towards community medicine means an infrastructure has grown up to administer these medicines in the home and to run clinical trials in the same way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Graham Wylie is CEO of the Medical Research Network Ltd, an affiliate company of Healthcare at Home. Graham, who trained as a physician, has 18 years of experience in clinical trials, starting with 10 years at Pfizer in clinical development and corporate HQ, with roles ranging from project management of trials to global implementation of standard trial processes and IT tools. He then joined Parexel International in 1999 as Medical Director for Northern Europe, progressing to Vice President of Account Management for Europe by 2003. In 2005 he joined Healthcare at Home to develop their clinical trials activities into a full business unit, known as ‘The Medical Research Network’, spinning the division off as a separate company in 2006.
spacer
Dr Graham Wylie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

The Process of Informed Consent (written by ACRP)

CenterWatch

Every investigator and clinical research coordinator (CRC) should recognize the importance of obtaining valid and appropriate informed consent as an important protection of the rights and welfare of human subjects. The purpose of this ACRP guidance document is not to provide a literature review or summarize the recommendations of various working groups. Instead, the Association decided it would be helpful to provide short and focused guidance which describes how to best structure the informed consent process in accordance with best practices.
More info >>

 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement